MEDFORD, N.Y., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ: CEMI) (“Chembio”), a provider of point-of-care diagnostic tests for infectious diseases, announced today that it has commenced an underwritten registered public offering of its common stock. In addition, Chembio intends to grant the underwriter a 30-day option to purchase additional shares, in a number equal to up to 15% of the number of shares of common stock sold in the offering, to cover over-allotments, if any. All shares of common stock to be sold in the proposed offering will be offered by Chembio. The proposed offering is subject to market and other conditions, as well as customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.
Chembio intends to use the net proceeds from the offering to fund its proposed acquisition of opTricon GmbH announced on October 22nd, to support its business growth strategy, including broadening U.S. manufacturing automation and expanding and improving facilities, and for other general corporate purposes.
Craig-Hallum Capital Group LLC is acting as sole managing underwriter for the proposed offering.
A shelf registration statement on Form S-3 (No. 333-227398) relating to the shares of common stock to be issued in the proposed offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) and is effective. In addition to this shelf registration statement, a preliminary prospectus supplement and accompanying base prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus may be obtained by contacting Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, by telephone at 612-334-6300 or by email at firstname.lastname@example.org. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The Company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
Lynn Pieper Lewis